ADVIL PM (diphenhydramine hcl, ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2005.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
ADVIL PM is a fixed-dose combination of ibuprofen (NSAID) and diphenhydramine HCl (antihistamine) formulated as an oral capsule for over-the-counter use. It is indicated for temporary relief of minor aches and pains with accompanying sleeplessness. The ibuprofen provides cyclooxygenase inhibition for anti-inflammatory and analgesic effects, while diphenhydramine induces somnolence to facilitate sleep.
As a mature OTC product approaching loss of exclusivity, the brand team is likely focused on defensive line extensions and cost optimization rather than aggressive growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ADVIL PM offers limited career acceleration opportunities due to its mature, declining lifecycle stage and OTC classification. Roles on this product are primarily commercial/retail-focused, emphasizing cost management, promotional effectiveness, and retail distribution rather than clinical innovation or pipeline advancement.
Worked on ADVIL PM at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo